{"protocolSection": {"identificationModule": {"nctId": "NCT00296491", "orgStudyIdInfo": {"id": "ADA103575"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study Of Allergic Rhinitis In Patients Who Also Have Asthma", "officialTitle": "A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS\u00ae 100/50mcg BID or Placebo BID"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-09"}, "primaryCompletionDateStruct": {"date": "2007-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-23", "studyFirstSubmitQcDate": "2006-02-23", "studyFirstPostDateStruct": {"date": "2006-02-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2008-10-31", "resultsFirstSubmitQcDate": "2009-03-26", "resultsFirstPostDateStruct": {"date": "2009-05-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-03", "lastUpdatePostDateStruct": {"date": "2016-12-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.", "detailedDescription": "A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS\u00ae 100/50mcg BID or Placebo BID"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Allergic Rhinitis", "Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 725, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD", "interventionNames": ["Drug: fluticasone propionate/salmeterol (FSC)", "Drug: montelukast (MON)", "Drug: placebo nasal", "Drug: ADVAIR DISKUS"]}, {"label": "Fluticasone Propionate/Salmeterol (FSC)", "type": "ACTIVE_COMPARATOR", "description": "FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD", "interventionNames": ["Drug: fluticasone propionate/salmeterol (FSC)", "Drug: placebo nasal", "Drug: ADVAIR DISKUS", "Drug: placebo capsule"]}, {"label": "Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD", "interventionNames": ["Drug: fluticasone propionate/salmeterol (FSC)", "Drug: fluticasone propionate (FP)", "Drug: ADVAIR DISKUS", "Drug: placebo capsule"]}, {"label": "Montelukast (MON)", "type": "ACTIVE_COMPARATOR", "description": "Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD", "interventionNames": ["Drug: montelukast (MON)", "Drug: placebo nasal", "Drug: placebo DISKUS"]}], "interventions": [{"type": "DRUG", "name": "fluticasone propionate/salmeterol (FSC)", "description": "fluticasone propionate/salmeterol DISKUS combination", "armGroupLabels": ["Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "Fluticasone Propionate/Salmeterol (FSC)", "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"]}, {"type": "DRUG", "name": "montelukast (MON)", "description": "montelukast capsule", "armGroupLabels": ["Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)", "Montelukast (MON)"]}, {"type": "DRUG", "name": "fluticasone propionate (FP)", "description": "fluticasone propionate aqueous nasal spray", "armGroupLabels": ["Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)"]}, {"type": "DRUG", "name": "placebo nasal", "description": "vehicle placebo nasal spray", "armGroupLabels": ["Fluticasone Propionate/Salmeterol (FSC)", "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)", "Montelukast (MON)"]}, {"type": "DRUG", "name": "ADVAIR DISKUS", "description": "ADVAIR DISKUS", "armGroupLabels": ["Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "Fluticasone Propionate/Salmeterol (FSC)", "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"]}, {"type": "DRUG", "name": "placebo capsule", "description": "placebo capsule", "armGroupLabels": ["Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "Fluticasone Propionate/Salmeterol (FSC)"]}, {"type": "DRUG", "name": "placebo DISKUS", "description": "placebo DISKUS", "armGroupLabels": ["Montelukast (MON)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Mean Change From Baseline at Endpoint in Morning Peak Expiratory Flow (PEF) for Per Protocol Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}], "secondaryOutcomes": [{"measure": "Rhinitis: Mean Change From Baseline at 1-2 Weeks in Daytime Total Nasal Symptom Scores (D-TNNS).", "description": "The sum of scores of each of the four daytime symptoms (nasal congestion, itching, rhinorrhea, and sneezing). Scale: 0=none (no sign/symptom evident)1=mild (sign/symptom clearly present; easily tolerated)2=moderate (definite awareness of sign/symptom that is bothersome but tolerable)3=severe (sign/symptom is hard to tolerate)", "timeFrame": "Baseline to 1-2 Weeks"}, {"measure": "Rhinitis: Mean Change From Baseline at 1-2 Weeks in Nightime Total Nasal Symptom Scores (N-TNSS)", "description": "The scores of 3 nighttime symptoms (nasal congestion upon awakening, difficulty going to sleep due to nasal symptoms, nighttime awakenings due to nasal symptoms). Scale: 0=not noticeable, 1=noticeable but not bothersome, 2=noticeable and bothersome some of the time, 3=bothersome most of the time and/or very bothersome some of the time.", "timeFrame": "Baseline To 1-2 Weeks"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Per Protocol Population", "description": "Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment.Asthma symptom scores and the subject-rated overall satisfaction with treatment, related to the percentage of asthma symptom-free days. Same scale used as in outcome 8.", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Per Protocol Population", "description": "Asthma symptom score:0=no symptoms,1=symptoms 1 short period,2=symptoms 2 or more short periods,3=symptoms most of day not affect activities,4=symptoms most of day did affect activities,5=symptoms severe.Overall satisfaction score:0=very dissatisfied,1=dissatisfied,2=slightly dissatisfied,3=neutral,4=slightly satisfied,5=satisfied 6=very satisfied", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol-Salbutamol Free Days for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}, {"measure": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol/Salbutamol-Free Days for Per Protocol Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).", "timeFrame": "Baseline to Endpoint (weeks 3-4)"}]}, "eligibilityModule": {"eligibilityCriteria": "INCLUSION CRITERIA:\n\nA subject will be considered eligible for inclusion in this study only if all of the following criteria apply:\n\n* Consent: A signed and dated written informed consent must be obtained from the subject or subject's legally acceptable representative prior to study participation. An informed consent must be signed prior to any change in the subject's medication regimen, including withholding medications prior to Visit 1.\n* Gender: Male or female. Females are eligible to participate only if they are currently not pregnant and not lactating. Females of child-bearing potential will be required to use a highly effective method for avoiding pregnancy (i.e., contraception with a failure rate of \\<1% per year). Female subjects of child-bearing potential will undergo a urine pregnancy test at Visits 1, 2, 3, and 4. Any female who becomes pregnant during the study will be withdrawn. Female subjects should not be enrolled if they plan to become pregnant during the time of study participation.\n* Age: 15 years and older.\n* Asthma Diagnosis: A diagnosis of persistent asthma, for at least three months, as defined by the following American Thoracic Society definition:\n\nAsthma is a clinical syndrome characterized by increased responsiveness of the tracheobronchial tree to a variety of stimuli. The major symptoms of asthma are paroxysms of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or corticosteroids, or increased obstruction caused by drugs or other stimuli \\[American Thoracic Society, 1987a\\].\n\nNOTE: Intermittent and seasonal asthma, as well as exercise-induced bronchospasm alone, are excluded.\n\n* Asthma Therapy: 3 months' prior and current use of one of the following asthma therapies, with no change in regimen during the month prior to Visit 1:\n\n  * Scheduled or as-needed inhaled or oral short-acting beta2-agonist (SABA). Subjects must be able to replace their current short-acting beta2-agonist with albuterol/salbutamol, to be used only on an as-needed basis for the duration of the study.\n  * Allowed non-corticosteroid controller therapy (e.g., anticholinergics and cromolyn).\n  * One of the following inhaled corticosteroids taken at the corresponding daily dose:\n\ncriteria.\n\nInhaled Corticosteroid (Total Daily Dose) Beclomethasone dipropionate (\u2264420mcg) Beclomethasone dipropionate HFA (\u2264240mcg) Budesonide (\u2264400mcg) Flunisolide (\u22641000mcg) Fluticasone propionate inhalation aerosol (\u2264220mcg) Fluticasone propionate inhalation powder (\u2264250mcg) Mometasone furoate (\u2264220mcg) Triamcinolone acetonide (\u22641000mcg) Subjects taking ADVAIR 100/50mcg BID are eligible to replace ADVAIR with FLOVENT HFA 110mcg BID for 14 days prior to Visit 1. This change will be at the Investigator's clinical discretion, taking each individual's current and past asthma stability into account. The subject must be aware of the risks and benefits of switching their medication and acknowledge this by signing an informed consent prior to any change in the subject's medication regimen.\n\n* Asthma Severity: An FEV1 between 65% - 95% of predicted value at Visit 1 after withholding asthma medications as detailed in the protocol.\n\nAt Visit 2, subjects must also be experiencing minimum asthma symptoms as defined in Section 5.2.3, \"Randomization Criteria\", and in Section 6.2 of the protocol.\n\nPredicted FEV1 will be based on the National Health and Nutrition Examination Survey (NHANES III) predicted normal values \\[Hankinson, 1999\\].\n\n* Rhinitis Diagnosis: A diagnosis of seasonal allergic rhinitis defined as follows:\n\n  * A clinical history (written or verbal confirmation) of allergic rhinitis with the seasonal onset and offset of nasal allergy symptoms during each of the previous 2 relevant allergy seasons (captured in source documents only).\n\nAND \u2022A positive skin test reaction to a geographically relevant seasonal allergen, as determined by the skin prick method, within 24 months prior to or at Visit 1.\n\nFor the purposes of this study, a positive skin test reaction is defined as a wheal diameter that is at least 3mm greater than diluent control using 1:20 W:V glycerinated solution.\n\n\u2022At Visit 2, subjects must also be experiencing minimum rhinitis symptoms as defined in Section 5.2.3, \"Randomization Criteria\", and in Section 6.2 of the protocol.\n\n* Geographical Location: Active residence within a geographical region where exposure to a relevant seasonal allergen is expected to be significant during the entire study period.\n\nNote: The principal investigator is responsible for tracking and recording pollen counts for geographically relevant seasonal allergens throughout the entire study. Alternatively, this information may be obtained from a reputable source from within the same geographical area.\n\nEXCLUSION CRITERIA:\n\nA subject will not be eligible for inclusion in this study if any of the following criteria apply:\n\n* Currently Diagnosed with Life-Threatening Asthma: An episode or episodes of asthma requiring intubation associated with hypercapnia, respiratory arrest, or hypoxic seizures.\n* Asthma Instability: Hospitalization for asthma within 6 months of Visit 1.\n* Concurrent Respiratory Disease: Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, emphysema, or any other respiratory abnormalities other than asthma.\n* Nasal Obstruction: Severe physical obstruction of the nose (e.g., deviated septum) that could affect the deposition of double-blind intranasal study drug.\n* Nasal History: History of nasal septal perforation or recent nasal septal surgery.\n* Other Concurrent Conditions/Diseases: Any evidence of rhinitis medicamentosa, history of glaucoma and/or cataracts or ocular herpes simplex, or any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.\n\nThe list of additional excluded conditions/diseases includes, but is not limited to: cardiac arrhythmias; congestive heart failure; coronary artery disease; poorly controlled diabetes, poorly controlled hypertension, poorly controlled peptic ulcer, hematologic, hepatic, or renal disease; immunologic compromise; current malignancy; current or quiescent tuberculosis, and Cushing's or Addison's disease.\n\n* Drug Allergy: Any immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, leukotriene modifier, or any intranasal, inhaled, or systemic corticosteroid therapy, or sensitivity to aspirin or other NSAIDS. Subjects with severe milk protein allergies are also excluded from participation.\n* Respiratory Tract Infections: Any sinus, middle ear, oropharyngeal, upper or lower respiratory tract infection that has not resolved at least 14 days immediately preceding Visit 1, or for which antibiotic therapy has not been completed at least 14 days prior to Visit 1.\n* Concurrent Medications: Concurrent use of any of the following medications that may affect the course of asthma, rhinitis, or interact with sympathomimetic amines or montelukast.\n\n  * Beta-blockers\n  * tricyclic antidepressants\n  * monoamine oxidase inhibitors\n  * phenobarbital\n  * rifampin\n  * ritonavir\n  * ketoconazole\n* Systemic Corticosteroids: Use of oral or parenteral systemic corticosteroids within 28 days of Visit 1, or requirement for more than two courses of parenteral systemic corticosteroids for asthma within 6 months of Visit 1.\n\nNOTE: Topical hydrocortisone cream or ointment (1% or less) is permitted during the study.\n\n* Excluded Rhinitis Medications: The following rhinitis medications must be withheld during the corresponding \"exclusion period\" prior to Visit 1 and are not allowed any time during the study, unless dispensed as double-blind study drug:\n\nMedication (Exclusion Period Prior to Visit 1) Intranasal and ocular corticosteroids (28 days) Leukotriene modifiers (e.g., Singulair, Accolate, Zyflo) (28 days) Intranasal and ocular cromolyn (14 days) Long-acting antihistamines (e.g., loratadine, cetirizine) (10 days) Short-acting antihistamines (includes prescription and OTC) (72 hours) Oral and intranasal decongestants (72 hours) Intranasal anticholinergics (e.g., Atrovent) (24 hours)\n\n* Excluded Asthma Medications: The following asthma medications must be withheld during the corresponding \"exclusion period\" prior to Visit 1.\n\nThese asthma medications, with the exception of an inhaled corticosteroid/long-acting beta2-agonist combination product and Xolair, may be continued during the run-in period of the study (between Visits 1 and 2), but must be withheld prior to Visit 2 for the appropriate \"exclusion period\" as shown below.\n\nThese asthma medications are not allowed any time after randomization at Visit 2 (with the exception of as as-needed rescue albuterol/salbutamol), unless dispensed as double-blind study drug:\n\nMedication\u00aa (Exclusion Period Prior to Visit 1 and/or Visit 2) Inhaled corticosteroid/long-acting beta2-agonist combination product (e.g., ADVAIR) (14 days) Inhaled anticholinergics (e.g., Atrovent, Combivent, Spiriva) (24 hours) Theophylline products (48 hours) Inhaled cromolyn or nedocromil (24 hours) Inhaled corticosteroids (12 hours) Long-acting beta2-agonists (e.g., Foradil, SEREVENT\u2122) (14 days) Oral beta2-agonists (12 hours) Inhaled short-acting beta2-agonists\\^b (e.g., Proventil) (6 hours) Xolair (12 months)\n\n1. For the leukotriene modifier \"exclusion period\" prior to Visit 1, refer to Exclusion Criterion 11.\n2. Replaced at Visit 1 with albuterol/salbutamol.\n\n   * Ophthalmic preparations: Use of artificial tears, eyewashes, homeopathic preparations, irrigation solutions, lubricants, sympathomimetic preparations, vasoconstrictors, or combinations of any of the aforementioned products during the study.\n   * Immunosuppressive Medications: Use of immunosuppressive medications during the study.\n\nNOTE: Immunotherapy for the treatment of allergies is allowed during the study, provided that it was not initiated within 30 days of Visit 1, the dose has remained fixed over the 30 days prior to Visit 1, and the dose will remain fixed for the duration of the study.\n\n* Positive Pregnancy Test: A positive pregnancy test at Visit 1.\n* Tobacco Use: Greater than a 10 pack-year history of cigarette smoking or use of any tobacco products within 1 year of Visit 1. This includes cigarettes, cigars, pipe, chewing tobacco, and snuff.\n\nNote: Pack years = number of cigarettes smoked per day divided by 20, multiplied by the number of years of smoking.\n\n* Questionable Validity of Consent: Any infirmity or disability that would limit the subject's consent or geographic location that would limit the compliance for scheduled visits.\n* Investigational Medications: Use of any investigational drug within 30 days of Visit 1.\n* 3rd shift/Nighttime employment: Any employment during the nighttime hours (10 p.m. - 6 a.m.) or 3rd shift.\n* Site affiliation: Participation of anyone associated with the administration of the study or their immediate family members", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Glendale", "state": "Arizona", "zip": "85304", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "GSK Investigational Site", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "GSK Investigational Site", "city": "Tucson", "state": "Arizona", "zip": "85712", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "GSK Investigational Site", "city": "Hot Springs", "state": "Arkansas", "zip": "71913", "country": "United States", "geoPoint": {"lat": 34.5037, "lon": -93.05518}}, {"facility": "GSK Investigational Site", "city": "Berkeley", "state": "California", "zip": "94705", "country": "United States", "geoPoint": {"lat": 37.87159, "lon": -122.27275}}, {"facility": "GSK Investigational Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Rancho Mirage", "state": "California", "zip": "92270", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Roseville", "state": "California", "zip": "95678", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "GSK Investigational Site", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "GSK Investigational Site", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "GSK Investigational Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "GSK Investigational Site", "city": "San Jose", "state": "California", "zip": "95128", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "GSK Investigational Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "GSK Investigational Site", "city": "Vista", "state": "California", "zip": "92083", "country": "United States", "geoPoint": {"lat": 33.20004, "lon": -117.24254}}, {"facility": "GSK Investigational Site", "city": "Boulder", "state": "Colorado", "zip": "80304", "country": "United States", "geoPoint": {"lat": 40.01499, "lon": -105.27055}}, {"facility": "GSK Investigational Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "GSK Investigational Site", "city": "Fort Collins", "state": "Colorado", "zip": "80526", "country": "United States", "geoPoint": {"lat": 40.58526, "lon": -105.08442}}, {"facility": "GSK Investigational Site", "city": "Lakewood", "state": "Colorado", "zip": "80401", "country": "United States", "geoPoint": {"lat": 39.70471, "lon": -105.08137}}, {"facility": "GSK Investigational Site", "city": "Brandon", "state": "Florida", "zip": "33511", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "GSK Investigational Site", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "GSK Investigational Site", "city": "Ocala", "state": "Florida", "zip": "34471", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "GSK Investigational Site", "city": "Pensacola", "state": "Florida", "zip": "32504", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "GSK Investigational Site", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "GSK Investigational Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "GSK Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30342", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "GSK Investigational Site", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "GSK Investigational Site", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "GSK Investigational Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30045", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "GSK Investigational Site", "city": "Savannah", "state": "Georgia", "zip": "31405", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "GSK Investigational Site", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "GSK Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "GSK Investigational Site", "city": "Springfield", "state": "Illinois", "zip": "62704", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "GSK Investigational Site", "city": "Indianapolis", "state": "Indiana", "zip": "46208", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "GSK Investigational Site", "city": "South Bend", "state": "Indiana", "zip": "46617", "country": "United States", "geoPoint": {"lat": 41.68338, "lon": -86.25001}}, {"facility": "GSK Investigational Site", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "GSK Investigational Site", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "GSK Investigational Site", "city": "Lexington", "state": "Kentucky", "zip": "40536", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "GSK Investigational Site", "city": "Louisville", "state": "Kentucky", "zip": "40215", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "GSK Investigational Site", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "GSK Investigational Site", "city": "Baton Rouge", "state": "Louisiana", "zip": "70808", "country": "United States", "geoPoint": {"lat": 30.45075, "lon": -91.15455}}, {"facility": "GSK Investigational Site", "city": "Covington", "state": "Louisiana", "zip": "70433", "country": "United States", "geoPoint": {"lat": 30.47549, "lon": -90.10042}}, {"facility": "GSK Investigational Site", "city": "Lafayette", "state": "Louisiana", "zip": "70503", "country": "United States", "geoPoint": {"lat": 30.22409, "lon": -92.01984}}, {"facility": "GSK Investigational Site", "city": "Shreveport", "state": "Louisiana", "zip": "71105", "country": "United States", "geoPoint": {"lat": 32.52515, "lon": -93.75018}}, {"facility": "GSK Investigational Site", "city": "Sunset", "state": "Louisiana", "zip": "70584", "country": "United States", "geoPoint": {"lat": 30.41131, "lon": -92.06845}}, {"facility": "GSK Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "GSK Investigational Site", "city": "North Andover", "state": "Massachusetts", "zip": "01845", "country": "United States", "geoPoint": {"lat": 42.6987, "lon": -71.13506}}, {"facility": "GSK Investigational Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "GSK Investigational Site", "city": "Jackson", "state": "Mississippi", "zip": "39202", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "GSK Investigational Site", "city": "Jefferson City", "state": "Missouri", "zip": "65101", "country": "United States", "geoPoint": {"lat": 38.5767, "lon": -92.17352}}, {"facility": "GSK Investigational Site", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "GSK Investigational Site", "city": "St. Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "GSK Investigational Site", "city": "Warrensburg", "state": "Missouri", "zip": "64093", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "GSK Investigational Site", "city": "Lincoln", "state": "Nebraska", "zip": "68505", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "GSK Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68124", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "GSK Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "GSK Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "GSK Investigational Site", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "GSK Investigational Site", "city": "Forked River", "state": "New Jersey", "zip": "08731", "country": "United States", "geoPoint": {"lat": 39.83984, "lon": -74.19014}}, {"facility": "GSK Investigational Site", "city": "Summit", "state": "New Jersey", "zip": "07091", "country": "United States", "geoPoint": {"lat": 40.71562, "lon": -74.36468}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "New York", "zip": "14618", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "GSK Investigational Site", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Parma", "state": "Ohio", "zip": "44129", "country": "United States", "geoPoint": {"lat": 41.40477, "lon": -81.72291}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Bend", "state": "Oregon", "zip": "97701", "country": "United States", "geoPoint": {"lat": 44.05817, "lon": -121.31531}}, {"facility": "GSK Investigational Site", "city": "Portland", "state": "Oregon", "zip": "97213", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "GSK Investigational Site", "city": "Providence", "state": "Rhode Island", "zip": "02906", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "GSK Investigational Site", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "GSK Investigational Site", "city": "Charleston", "state": "South Carolina", "zip": "29414", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "GSK Investigational Site", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "GSK Investigational Site", "city": "Orangeburg", "state": "South Carolina", "zip": "29118", "country": "United States", "geoPoint": {"lat": 33.49182, "lon": -80.85565}}, {"facility": "GSK Investigational Site", "city": "Simpsonville", "state": "South Carolina", "zip": "29681", "country": "United States", "geoPoint": {"lat": 34.73706, "lon": -82.25428}}, {"facility": "GSK Investigational Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "GSK Investigational Site", "city": "Chattanooga", "state": "Tennessee", "zip": "37421", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "GSK Investigational Site", "city": "Germantown", "state": "Tennessee", "zip": "38138", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"facility": "GSK Investigational Site", "city": "Knoxville", "state": "Tennessee", "zip": "37909", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "GSK Investigational Site", "city": "Savannah", "state": "Tennessee", "zip": "38372", "country": "United States", "geoPoint": {"lat": 35.2248, "lon": -88.2492}}, {"facility": "GSK Investigational Site", "city": "Austin", "state": "Texas", "zip": "78750", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75231-4307", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75240", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "El Paso", "state": "Texas", "zip": "79902", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "GSK Investigational Site", "city": "El Paso", "state": "Texas", "zip": "79925", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77070", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "Kerrville", "state": "Texas", "zip": "78028", "country": "United States", "geoPoint": {"lat": 30.04743, "lon": -99.14032}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78205", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78233", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Waco", "state": "Texas", "zip": "76708", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "GSK Investigational Site", "city": "Salt Lake City", "state": "Utah", "zip": "84121", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "GSK Investigational Site", "city": "West Jordan", "state": "Utah", "zip": "84084", "country": "United States", "geoPoint": {"lat": 40.60967, "lon": -111.9391}}, {"facility": "GSK Investigational Site", "city": "Danville", "state": "Virginia", "zip": "24541", "country": "United States", "geoPoint": {"lat": 36.58597, "lon": -79.39502}}, {"facility": "GSK Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "GSK Investigational Site", "city": "Kirkland", "state": "Washington", "zip": "98034", "country": "United States", "geoPoint": {"lat": 47.68149, "lon": -122.20874}}, {"facility": "GSK Investigational Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R3C 0N2", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "GSK Investigational Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "GSK Investigational Site", "city": "Brampton", "state": "Ontario", "zip": "L6T 3T1", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "GSK Investigational Site", "city": "Kanata", "state": "Ontario", "zip": "K2L 3C8", "country": "Canada", "geoPoint": {"lat": 45.3001, "lon": -75.91606}}, {"facility": "GSK Investigational Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "GSK Investigational Site", "city": "Niagara Falls", "state": "Ontario", "zip": "L2G 1J4", "country": "Canada", "geoPoint": {"lat": 43.10012, "lon": -79.06627}}, {"facility": "GSK Investigational Site", "city": "Ottawa", "state": "Ontario", "zip": "K1N 6N5", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "GSK Investigational Site", "city": "Ottawa", "state": "Ontario", "zip": "K2C 3R2", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "GSK Investigational Site", "city": "Sudbury", "state": "Ontario", "zip": "P3E 1H5", "country": "Canada", "geoPoint": {"lat": 46.49, "lon": -80.99001}}, {"facility": "GSK Investigational Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4M6", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "GSK Investigational Site", "city": "Trois Rivi\u00e8res", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "GSK Investigational Site", "city": "Tallinn", "zip": "13419", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "GSK Investigational Site", "city": "Tartu", "zip": "51014", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "GSK Investigational Site", "city": "Bialystok", "zip": "15-025", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "GSK Investigational Site", "city": "Bialystok", "zip": "15-274", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-023", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Lodz", "zip": "93-513", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}]}, "referencesModule": {"references": [{"pmid": "20167147", "type": "DERIVED", "citation": "Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan-Feb;31(1):68-75. doi: 10.2500/aap.2010.31.3306."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "ADA103575", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "ADA103575", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Flut Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "description": "Flut Prop = Fluticasone Propionate."}, {"id": "FG001", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"}, {"id": "FG002", "title": "Fluticasone Propionate/Salmeterol (FSC)"}, {"id": "FG003", "title": "Montelukast (MON)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Please note: Outcome Measures generally conducts analysis of 2 of the 4 Arms at a time.", "numSubjects": "182"}, {"groupId": "FG001", "numSubjects": "182"}, {"groupId": "FG002", "numSubjects": "180"}, {"groupId": "FG003", "numSubjects": "181"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "140"}, {"groupId": "FG001", "numSubjects": "129"}, {"groupId": "FG002", "numSubjects": "137"}, {"groupId": "FG003", "numSubjects": "138"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "53"}, {"groupId": "FG002", "numSubjects": "43"}, {"groupId": "FG003", "numSubjects": "43"}]}], "dropWithdraws": [{"type": "Low Pollen Counts", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "25"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Withdrawn due to Asthma", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Non-Compliance", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)", "description": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) = FSC twice a day (BID), plus vehicle placebo nasal spray once a day (QD), plus MON once a day (QD)"}, {"id": "BG001", "title": "Fluticasone Propionate/Salmeterol (FSC)", "description": "Fluticasone Propionate/Salmeterol (FSC) = FSC BID, plus vehicle placebo nasal spray once a day (QD), plus placebo capsule once a day (QD)."}, {"id": "BG002", "title": "Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "description": "Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) = FSC twice a day (BID), plus FPANS (once a day) QD, plus placebo capsule once a day (QD)."}, {"id": "BG003", "title": "Montelukast (MON)", "description": "Montelukast (MON) = Placebo DISKUS BID, plus vehicle placebo nasal spray once a day (QD), plus MON (once a day) QD."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "182"}, {"groupId": "BG001", "value": "180"}, {"groupId": "BG002", "value": "182"}, {"groupId": "BG003", "value": "181"}, {"groupId": "BG004", "value": "725"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.0", "spread": "13.54"}, {"groupId": "BG001", "value": "34.5", "spread": "14.64"}, {"groupId": "BG002", "value": "34.9", "spread": "12.62"}, {"groupId": "BG003", "value": "34.5", "spread": "12.47"}, {"groupId": "BG004", "value": "34.2", "spread": "13.34"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "115"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "120"}, {"groupId": "BG003", "value": "112"}, {"groupId": "BG004", "value": "449"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "69"}, {"groupId": "BG004", "value": "276"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "138"}, {"groupId": "BG002", "value": "143"}, {"groupId": "BG003", "value": "145"}, {"groupId": "BG004", "value": "564"}]}]}, {"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "30"}, {"groupId": "BG004", "value": "130"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "2"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "24"}]}]}, {"title": "Native Hawaiian or other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "4"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC and MON in the context of asthma measures, included all subjects randomized to double-blind treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Prop/Salmeterol (FSC)"}, {"id": "OG001", "title": "Montelukast (MON)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.4", "spread": "4.10"}, {"groupId": "OG001", "value": "3.6", "spread": "3.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "23.2", "ciPctValue": "95", "ciLowerLimit": "12.5", "ciUpperLimit": "33.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.41", "estimateComment": "Treatment Difference = FSC - MON"}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline at Endpoint in Morning Peak Expiratory Flow (PEF) for Per Protocol Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.", "populationDescription": "The Per Protocol population, the basis for equivalence comparison between FSC and FSC+MON in terms of asthma measures, included subjects from the ITT population who did not deviate significantly from the protocol.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Flut Prop/Salmeterol/Montelukast (FSC+MON)"}, {"id": "OG001", "title": "Fluticasone Propionate/Salmeterol (FSC)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "30.9", "spread": "4.92"}, {"groupId": "OG001", "value": "35.2", "spread": "6.41"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Given estimates, and assuming a significance level of a=0.05, a sample size of 133 subjects per treatment was determined to be sufficient to provide 80% power to show equivalance.", "pValue": "<0.127", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-8.9", "ciPctValue": "95", "ciLowerLimit": "-24.6", "ciUpperLimit": "6.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "8.00", "estimateComment": "Treatment Difference=FSC+MON-FSC"}]}, {"type": "SECONDARY", "title": "Rhinitis: Mean Change From Baseline at 1-2 Weeks in Daytime Total Nasal Symptom Scores (D-TNNS).", "description": "The sum of scores of each of the four daytime symptoms (nasal congestion, itching, rhinorrhea, and sneezing). Scale: 0=none (no sign/symptom evident)1=mild (sign/symptom clearly present; easily tolerated)2=moderate (definite awareness of sign/symptom that is bothersome but tolerable)3=severe (sign/symptom is hard to tolerate)", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC+FPANS and FSC+MON in the context of rhinitis measures, included all subjects randomized to double-blind treatment. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Points on a Scale", "timeFrame": "Baseline to 1-2 Weeks", "groups": [{"id": "OG000", "title": "Fluticasone Prop/Salmeterol/Montelukast (FSC+MON)"}, {"id": "OG001", "title": "Fluticasone Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "0.16"}, {"groupId": "OG001", "value": "-3.0", "spread": "0.18"}]}]}]}, {"type": "SECONDARY", "title": "Rhinitis: Mean Change From Baseline at 1-2 Weeks in Nightime Total Nasal Symptom Scores (N-TNSS)", "description": "The scores of 3 nighttime symptoms (nasal congestion upon awakening, difficulty going to sleep due to nasal symptoms, nighttime awakenings due to nasal symptoms). Scale: 0=not noticeable, 1=noticeable but not bothersome, 2=noticeable and bothersome some of the time, 3=bothersome most of the time and/or very bothersome some of the time.", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC+FPANS and FSC+MON in the context of rhinitis measures, included all subjects randomized to double-blind treatment. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Points on a Scale", "timeFrame": "Baseline To 1-2 Weeks", "groups": [{"id": "OG000", "title": "Flut Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS)"}, {"id": "OG001", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "0.13"}, {"groupId": "OG001", "value": "1.7", "spread": "0.13"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC and MON in the context of asthma measures, included all subjects randomized to double-blind treatment. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/sec", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate/Salmeterol (FSC)"}, {"id": "OG001", "title": "Montelukast (MON)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "180"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.02"}, {"groupId": "OG001", "value": "0.04", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Per Protocol Population", "description": "Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.", "populationDescription": "The Per Protocol population, the basis for equivalence comparison between FSC and FSC+MON in terms of asthma measures, included subjects from the ITT population who did not deviate significantly from the protocol. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/sec", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"}, {"id": "OG001", "title": "Fluticasone Propionate/Salmeterol (FSC)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "spread": "0.04"}, {"groupId": "OG001", "value": "0.13", "spread": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment.Asthma symptom scores and the subject-rated overall satisfaction with treatment, related to the percentage of asthma symptom-free days. Same scale used as in outcome 8.", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC and MON in the context of asthma measures, included all subjects randomized to double-blind treatment. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of asthma symptom-free days", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate/Salmeterol (FSC)"}, {"id": "OG001", "title": "Montelukast (MON)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.8", "spread": "2.94"}, {"groupId": "OG001", "value": "26.1", "spread": "2.83"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Per Protocol Population", "description": "Asthma symptom score:0=no symptoms,1=symptoms 1 short period,2=symptoms 2 or more short periods,3=symptoms most of day not affect activities,4=symptoms most of day did affect activities,5=symptoms severe.Overall satisfaction score:0=very dissatisfied,1=dissatisfied,2=slightly dissatisfied,3=neutral,4=slightly satisfied,5=satisfied 6=very satisfied", "populationDescription": "The Per Protocol population, the basis for equivalence comparison between FSC and FSC+MON in terms of asthma measures, included subjects from the ITT population who did not deviate significantly from the protocol. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of asthma symptom-free days", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)"}, {"id": "OG001", "title": "Fluticasone Propionate/Salmeterol (FSC)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.8", "spread": "4.32"}, {"groupId": "OG001", "value": "37.1", "spread": "4.23"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol-Salbutamol Free Days for Intent-to-Treat Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).", "populationDescription": "The Intent-to-Treat (ITT) population, the basis for superiority comparisons between FSC and MON in the context of asthma measures, included all subjects randomized to double-blind treatment. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of rescue-free days", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate/Salmeterol (FSC)"}, {"id": "OG001", "title": "Montelukast (MON)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "179"}, {"groupId": "OG001", "value": "181"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.5", "spread": "2.84"}, {"groupId": "OG001", "value": "26.7", "spread": "2.92"}]}]}]}, {"type": "SECONDARY", "title": "Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol/Salbutamol-Free Days for Per Protocol Population", "description": "Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).", "populationDescription": "The Per Protocol population, the basis for equivalence comparison between FSC and FSC+MON in terms of asthma measures, included subjects from the ITT population who did not deviate significantly from the protocol. Families of secondary efficacy measures were each adjusted for multiplicity using Hochberg's method.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of rescue-free days", "timeFrame": "Baseline to Endpoint (weeks 3-4)", "groups": [{"id": "OG000", "title": "Fluticasone Propionate + Salmeterol & Montelukast (FSC+MON)"}, {"id": "OG001", "title": "Fluticasone Propionate/Salmeterol (FSC)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.2", "spread": "3.97"}, {"groupId": "OG001", "value": "42.9", "spread": "4.20"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)", "description": "Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) = FSC twice a day (BID), plus FPANS (once a day) QD, plus placebo capsule once a day (QD).", "seriousNumAffected": 0, "seriousNumAtRisk": 182, "otherNumAffected": 32, "otherNumAtRisk": 182}, {"id": "EG001", "title": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)", "description": "Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) = FSC twice a day (BID), plus vehicle placebo nasal spray once a day (QD), plus MON once a day (QD)", "seriousNumAffected": 1, "seriousNumAtRisk": 182, "otherNumAffected": 32, "otherNumAtRisk": 182}, {"id": "EG002", "title": "Fluticasone Propionate/Salmeterol (FSC)", "description": "Fluticasone Propionate/Salmeterol (FSC) = FSC BID, plus vehicle placebo nasal spray once a day (QD), plus placebo capsule once a day (QD).", "seriousNumAffected": 1, "seriousNumAtRisk": 180, "otherNumAffected": 42, "otherNumAtRisk": 180}, {"id": "EG003", "title": "Montelukast (MON)", "description": "Montelukast (MON) = Placebo DISKUS BID, plus vehicle placebo nasal spray once a day (QD), plus MON (once a day) QD.", "seriousNumAffected": 1, "seriousNumAtRisk": 181, "otherNumAffected": 41, "otherNumAtRisk": 181}], "seriousEvents": [{"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 181}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Clostridial infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Eye infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Pharyngitis streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 181}]}, {"term": "Sinus headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Muscle twitching", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 181}]}, {"term": "Pharyngolaryngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 181}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Nasal discomfort", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Respiratory tract congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Dry throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Nasal dryness", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Rhinitis perennial", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Sinus congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 181}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 181}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 181}]}, {"term": "Food poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Oral pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Aphthous stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Stomach discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Arthropod sting", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Joint injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Joint sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Muscle strain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Neck injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Tooth fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 181}]}, {"term": "Menorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Metrorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 181}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Eye pruritis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Eye swelling", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Petechiae", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Anorgasmia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Middle insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Ear disorder", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 181}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Shoulder operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 182}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 182}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 180}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 181}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centres of a multi-centre trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000001249", "term": "Asthma"}, {"id": "D000065631", "term": "Rhinitis, Allergic"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M30545", "name": "Rhinitis, Allergic", "asFound": "Allergic Rhinitis", "relevance": "HIGH"}, {"id": "M9345", "name": "Rhinitis, Allergic, Seasonal", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Fabry Disease", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}